Private placement funds Phase 3 MSS colon cancer study
Agenus has secured a private placement worth about $85 million upfront and up to $340 million in total to fund ROBBIN1, its planned registrational Phase 3 trial in microsatellite-stable colon cancer.
If investors exercise all purchase warrants, the company expects the financing to support operations through year-end 2031. The deal includes up to $255 million in added gross proceeds from warrant exercises.
Commodore Capital led the financing. RA Capital Management, TCGX, Invus and Ligand Pharmaceuticals also took part.
Proceeds will back Agenus’ push to develop botensilimab and balstilimab, known as BOT+BAL, as a neoadjuvant treatment for microsatellite-stable, or MSS, colon cancer. The private placement is due to close on or about 15th July 2026, subject to customary conditions.
In the US, high-risk Stage II and Stage III MSS colon cancer affects about 38,000 patients each year. Worldwide, the figure tops 200,000, and Agenus put the US annual market opportunity above $7 billion.
No new curative-intent therapies have won approval for this setting in more than 20 years. As a result, Agenus is concentrating resources on a market with large unmet need.
ROBBIN1 Phase 3 schedule
ROBBIN1 is planned as a randomised global Phase 3 study in previously untreated high-risk Stage II and Stage III patients. Agenus has said the trial will enrol 850 patients, randomised 1:1, with event-free survival as the primary endpoint.
According to Agenus, the US Food and Drug Administration aligned with the company on the patient population, experimental regimen, control arm, primary endpoint and interim analysis plan.
First patient dosing is expected in the first quarter of 2027. Interim pathologic response data are expected in the second half of 2027, followed by an interim event-free survival analysis in the second half of 2029 and a final analysis in the second half of 2030.
Meanwhile, Agenus will stop financial support for the BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer. The company plans that change as it shifts money to the neoadjuvant programme.
Agenus said it will keep meeting obligations to patients already on treatment. It also plans to work with the Canadian Cancer Trials Group and trial investigators on the transition.
Chief Medical Officer Dr Steven O’Day said MSS colon cancer has “resisted standard checkpoint inhibitors” and argued that the neoadjuvant setting gives BOT+BAL its best chance to deliver a durable immune response.
Under the agreement, Agenus will issue 23,035,227 common shares, or pre-funded warrants instead of shares in some cases. It will also issue Series A warrants for 21,144,277 shares and Series B warrants for 33,797,214 shares.
Separately, the company agreed to expand its board to nine directors and appoint two Commodore Capital Master LP designees to new Class III seats. Agenus also scheduled a conference call and webcast for 8:30 a.m. ET on 14th July 2026.
